GO
Loading...

Novartis AG

More

  • FACTBOX-M&A frenzy transforming global pharma Monday, 14 Jul 2014 | 9:27 AM ET

    July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • *France's Servier, Israel's Teva among those fined. BRUSSELS, July 9- European Union antitrust regulators fined French drugmaker Servier, Israel's Teva and four others a total of 428 million euros on Wednesday, as they crack down on deals which block cheaper generic medicine.

  • *EU shift to Avastin a threat to Novartis, Bayer profits. PARIS, July 8- French lawmakers voted on Tuesday to allow the use of Roche's cancer drug Avastin as a cheap alternative eye treatment, in a budget-minded move critics fear could put patients' health- and company profits- at risk.

  • TEL AVIV, July 3- Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration, aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis.

  • FRANKFURT, July 1- German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone- each worth more than $1 billion- Bayer said it was not planning to untie the Merck bundle it secured in May in a competitive bidding tussle with Reckitt Benckiser, Procter& Gamble Co and Novartis.

  • Early movers: NFLX, WYNN, APP & more Tuesday, 1 Jul 2014 | 7:56 AM ET

    Some of the names on the move ahead of the open.

  • FRANKFURT, July 1- German drugmaker Bayer said it would keep the Dr. Scholl's and Coppertone- each worth more than $1 billion- Bayer said it was not planning to untie the Merck bundle it secured in May in a competitive bidding tussle with Reckitt Benckiser, Procter& Gamble Co and Novartis.

  • TOKYO, July 1- Tokyo prosecutors said on Tuesday they will charge the Japanese unit of Novartis AG and a former employee in connection with allegations of data manipulation in promoting its best-selling blood pressure drug Diovan.

  • WASHINGTON/ MUMBAI, June 27- India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.

  • *Move bolsters Shire in defence against AbbVie. *AbbVie to put its case to Shire shareholders- source. LONDON, June 25- Shire, which has spurned a $46 billion takeover offer from U.S. group AbbVie as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse.

  • *European Commission declines to comment. BRUSSELS, June 19- EU antitrust regulators are set to fine French drugmaker Servier, Israel's Teva and several of their peers next month for blocking cheaper generic medicine, two people with knowledge of the matter said on Thursday.

  • June 17- Pfizer Inc and rival Swiss drugmaker Novartis AG on Tuesday said they had asked U.S. regulators to approve their vaccines to prevent meningitis infections in people aged 10 to 25..

  • Will ghoulish investments pay off? Monday, 16 Jun 2014 | 6:57 PM ET
    Elderly women wait for lunch to be served at a day care facility on Gogo Island in Matsuyama, Ehime Prefecture, Japan

    As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.

  • June 16- A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.

  • Medtronic’s $43B Covidien deal: More to come? Monday, 16 Jun 2014 | 9:26 AM ET
    Medtronic Chairman and Chief Executive Omar Ishrak.

    Medtronic's $43 billion Covidien deal may signal future medical-device company mergers.

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • *Barclays recommendation upgrade lifts Novartis. PARIS, June 10- European stocks inched up on Tuesday, extending a three-week rally, led by gains in defensive Swiss blue-chips such as pharma group Novartis, boosted by an upbeat broker note.

  • *Gemalto boosted by Chinese contract. PARIS, June 10- European equities climbed to new peaks on Tuesday, with Germany's DAX stock market setting a new record high.